Results 31 to 40 of about 4,376,584 (354)

Interstitial Lung Disease in the Elderly [PDF]

open access: yesChest, 2017
Despite the relationship between idiopathic pulmonary fibrosis (IPF) and advancing age, little is known about the epidemiology of interstitial lung disease (ILD) in the elderly. We describe the diagnoses, clinical characteristics, and outcomes of patients who were elderly at the time of ILD diagnosis.Among subjects from a prospective cohort study of ...
Patterson, Karen C   +11 more
openaire   +2 more sources

Fibroblast Activation Protein–Specific PET/CT Imaging in Fibrotic Interstitial Lung Diseases and Lung Cancer: A Translational Exploratory Study

open access: yesJournal of Nuclear Medicine, 2021
Visual Abstract Interstitial lung diseases (ILDs) comprise over 200 parenchymal lung disorders. Among them, fibrosing ILDs, especially idiopathic pulmonary fibrosis, are associated with a poor prognosis, whereas some other ILDs, such as sarcoidosis, have
M. Röhrich   +15 more
semanticscholar   +1 more source

Distinct metabolic features in the plasma of patients with silicosis and dust-exposed workers in China: a case–control study

open access: yesBMC Pulmonary Medicine, 2021
Background Silicosis is a progressive pneumoconiosis characterized by interstitial fibrosis following exposure to silica dust. The role of metabolic dysregulation in the pathogenesis of silicosis has not been investigated in detail.
Changjiang Xue   +4 more
doaj   +1 more source

The prevalence and burden of interstitial lung diseases in the USA

open access: yesERJ Open Research, 2021
Interstitial lung diseases (ILDs) are a heterogeneous group of diseases (i.e. idiopathic interstitial pneumonias, autoimmune ILDs, environmental exposure-related ILDs, sarcoidosis) but share several common clinical and pathophysiological features [1, 2].
N. Jeganathan, Matheni Sathananthan
semanticscholar   +1 more source

Cluster features in fibrosing interstitial lung disease and associations with prognosis

open access: yesBMC Pulmonary Medicine, 2023
Background Clustering is helpful in identifying subtypes in complex fibrosing interstitial lung disease (F-ILD) and associating them with prognosis at an early stage of the disease to improve treatment management.
Yuanying Wang   +5 more
doaj   +1 more source

Role of the Microbiome in Interstitial Lung Diseases

open access: yesFrontiers in Medicine, 2021
There are trillions of microorganisms in the human body, consisting of bacteria, viruses, fungi, and archaea; these collectively make up the microbiome. Recent studies suggest that the microbiome may serve as a biomarker for disease, a therapeutic target,
O. Chioma   +3 more
semanticscholar   +1 more source

Study protocol of an international patient-led registry in patients with pulmonary fibrosis using online home monitoring: I-FILE

open access: yesBMC Pulmonary Medicine, 2023
Background Pulmonary fibrosis (PF) is caused by a heterogeneous group of diseases, with a high inter-individual variability in disease trajectory. Identifying disease progression in patients with PF has impact on clinical management decisions.
Gizal Nakshbandi   +9 more
doaj   +1 more source

Elevated Serum Amyloid a Levels Are not Specific for Sarcoidosis but Associate with a Fibrotic Pulmonary Phenotype

open access: yesCells, 2021
Elevated Serum Amyloid A (SAA) levels have been found in several inflammatory diseases, including sarcoidosis. SAA is suggested to be involved in sarcoidosis pathogenesis by involvement in granuloma formation and maintenance.
Els Beijer   +5 more
doaj   +1 more source

Interstitial lung disease [PDF]

open access: yesEuropean Respiratory Review, 2013
This article reviews the most important articles published in interstitial lung disease, as reviewed during the Clinical Year in Review session at the 2012 annual European Respiratory Society Congress in Vienna, Austria.Since the recent international guidelines for the management of idiopathic pulmonary fibrosis (IPF), important new evidence is ...
openaire   +4 more sources

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.

open access: yesNew England Journal of Medicine, 2019
BACKGROUND Preclinical data have suggested that nintedanib, an intracellular inhibitor of tyrosine kinases, inhibits processes involved in the progression of lung fibrosis.
K. Flaherty   +17 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy